$Xeris Pharmaceuticals (XERS.US)$ Xeris Expects to Exceed Full-Year 2024 Financial Guidance 4 minutes ago, 4:00 AM PST Via BusinessWire XERS Share Full-year 2024 total revenue projected to be $203 million, exceeding previous guidance of $198-$202 million Year-end 2024 cash position expected to be over $71 million, generating positive cash flow in the fourth quarter Recorlev® net revenue Q4 2024 anticipated to increase by approximately $5 million or 28% sequentially 2024 financial results ...
$Xeris Pharmaceuticals (XERS.US)$Xeris Biopharma Reports Preliminary Q2 Total Revenue To Exceed $47M, Representing Over 23% Growth Over Last Year; Estimate $44.894M
$Xeris Pharmaceuticals (XERS.US)$Xeris Biopharma Holdings Inc - FDA End-of-Phase 2 Interaction to Facilitate a Phase 3 Pivotal Study Program Is Expected by Year-End
$Xeris Pharmaceuticals (XERS.US)$ Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121) Xeris Biopharma announced positive topline results from its Phase 2 study of XP-8121, a once-weekly subcutaneous levothyroxine (SC) formulation. The study showed that XP-8121 provides predictable bioavailability and sustained levothyroxine levels, achieving normalized TSH/T4 levels with 45% less drug...
$Xeris Pharmaceuticals (XERS.US)$Reuters· 1 min ago Xeris Biopharma: Potential to Get Development Payments, Plus Low Double-Digit Royalties Based on Future Sales of Xeris Glucagon for Pumps, Pump Systems
Despite Xeris Biopharma Holdings' strong performance, its growth projections are subdued compared to the industry. This could lead to a share price decline if the P/S ratio falls to align with the growth outlook.
Xeris Pharmaceuticals Stock Forum
Xeris Expects to Exceed Full-Year 2024 Financial Guidance
4 minutes ago, 4:00 AM PST
Via BusinessWire
XERS
Share
Full-year 2024 total revenue projected to be $203 million, exceeding previous guidance of $198-$202 million
Year-end 2024 cash position expected to be over $71 million, generating positive cash flow in the fourth quarter
Recorlev® net revenue Q4 2024 anticipated to increase by approximately $5 million or 28% sequentially
2024 financial results ...
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
Xeris Biopharma announced positive topline results from its Phase 2 study of XP-8121, a once-weekly subcutaneous levothyroxine (SC) formulation. The study showed that XP-8121 provides predictable bioavailability and sustained levothyroxine levels, achieving normalized TSH/T4 levels with 45% less drug...
Xeris Biopharma: Potential to Get Development Payments, Plus Low Double-Digit Royalties Based on Future Sales of Xeris Glucagon for Pumps, Pump Systems
No comment yet